Poor
Needs Major Revision
Patient Risk:
Moderate
Summary
The response includes three statements, but none are supported by the prescribing information excerpts provided (Sections 1, 2, 4, 5, 6, 7, 8, 12, 14 were referenced generally, while only 2.4/2.5 and 5.1/5.3/17 counseling were supplied). Therefore, most claims are unsupported relative to the label information available for evaluation.
Category Scores
Accurate Statements
The labeling explicitly states that premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.
Supported by Section 5.1 text provided: 'Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.'
Epidural/spinal hematoma risk is described for neuraxial anesthesia or spinal puncture in patients treated with antithrombotic agents; events can result in long-term or permanent paralysis.
Supported by Section 5.3 text provided.
Unsupported Statements
The first Eliquis patent, US7868155, which covers apixaban + apivarfarin, is set to expire on April 1, 2028.
No prescribing information excerpt provided for patent timelines or the specific patent number/expiration date.
Patent expiration does not automatically mean generic versions will become available immediately.
No prescribing information excerpt provided addressing generic availability timelines or how patent expiration affects generic launch.
A biosimilar version of Eliquis developed by Mitsubishi Tanabe Pharma is currently in the approval process with the FDA.
No prescribing information excerpt provided addressing biosimilar development status, sponsor, or FDA approval process.
Contradictions
Important Omissions
If the intent was to provide label-based counseling/warning content, the response did not include the specific label conditions and instructions shown in the provided excerpts (e.g., Section 5.1 includes the condition 'in the absence of adequate alternative anticoagulation'; Section 5.3 includes specific timing for catheter removal and next dose).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because most statements are unsupported by the provided prescribing information excerpts (including patent/biosimilar availability claims), there is a moderate risk that users may rely on non-label information in contexts where the label is required. The two warning-related statements that were included are consistent with the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Major Revision
Primary Issue
Multiple statements (patent expiration date, implications for generics, and biosimilar development/approval status) are not supported by the provided FDA label excerpts and therefore should be removed or replaced with label-supported content.
Suggested Improvement
Limit claims to text supported by the supplied prescribing information excerpts (e.g., Section 5.1 discontinuation warning and Section 5.3 neuraxial anesthesia/puncture timing/monitoring guidance, plus Section 17 patient counseling). Exclude patent and biosimilar approval-status statements unless the exact FDA label excerpt addressing them is provided.